SGLT2 inhibitor approved as first new renal drug in 20 years

A chronic kidney disease indication for dapagliflozin will likely reduce transplantation and mortality, clinicians say

Patients with chronic kidney disease can now be prescribed dapagliflozin regardless of diabetes status after the TGA approved its use to halt decline in renal function.


Last week, the regulator updated the product information for the SGLT2 inhibitor to include a new indication for adults with chronic kidney disease (CKD) stage 2-4 and urinary albumin-to-creatinine ratio of 30mg/g or more.

Although dapagliflozin was already indicated for glycaemic control and heart failure with reduced ejection fraction, the move represented the first